Min Fang

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

InSilico Medicine Cayman TopCo is a holding company, which engages in the research and development of generative artificial intelligence (AI) driven therapeutic pipeline and software licensing. Its pipeline targets areas include high unmet needs, with a footprint in fibrosis, oncology, immunology, and other therapeutic areas. The company was founded by Alex Zhavoronkov on November 19, 2018 and is headquartered in Hong Kong.

Part of InSilico Medicine Hong Kong Ltd., InSilico Medicine, Inc. is a clinical stage biotechnology company based in New York, NY. InSilico Medicine is focused on generative models, reinforcement learning, and other modern machine learning techniques for the generation of new molecular structures with specified parameters, generation of synthetic biological data, target identification, and prediction of clinical trials outcomes. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. InSilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. The company was founded in 2014 by Aleksandr Aliper and Aleksandrs Zhavoronkov. Aleksandrs Zhavoronkov has been the CEO since 2014.